Cargando…
MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease
Gestational trophoblastic disease (GTD) is a group of highly aggressive, rare tumors. Human chorionic gonadotropin is a common biomarker used in the diagnosis and monitoring of GTD. To improve our knowledge of the pathology of GTD, we performed protein-peptide profiling on the urine of patients affe...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409522/ https://www.ncbi.nlm.nih.gov/pubmed/30744112 http://dx.doi.org/10.3390/metabo9020030 |
_version_ | 1783401990176374784 |
---|---|
author | Banach, Paulina Dereziński, Paweł Matuszewska, Eliza Matysiak, Jan Bochyński, Hubert Kokot, Zenon J. Nowak-Markwitz, Ewa |
author_facet | Banach, Paulina Dereziński, Paweł Matuszewska, Eliza Matysiak, Jan Bochyński, Hubert Kokot, Zenon J. Nowak-Markwitz, Ewa |
author_sort | Banach, Paulina |
collection | PubMed |
description | Gestational trophoblastic disease (GTD) is a group of highly aggressive, rare tumors. Human chorionic gonadotropin is a common biomarker used in the diagnosis and monitoring of GTD. To improve our knowledge of the pathology of GTD, we performed protein-peptide profiling on the urine of patients affected with gestational trophoblastic neoplasm (GTN). We analyzed urine samples from patients diagnosed with GTN (n = 26) and from healthy pregnant and non-pregnant controls (n = 17) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Ions were examined in a linear mode over a m/z range of 1000–10,000. All GTN urine samples were analyzed before and after treatment and compared with those of the controls. The statistical analyses included multivariate classification algorithms as well as ROC curves. Urine sample analyses revealed there were significant differences in the composition of the ions between the evaluated groups. Comparing the pre-treatment and group with the pregnant controls, we identified two discriminatory proteins: hemoglobin subunit α (m/z = 1951.81) and complement C4A (m/z = 1895.43). Then, comparing urine samples from the post-treatment cases with those from the non-pregnant controls, we identified the peptides uromodulin fragments (m/z = 1682.34 and 1913.54) and complement C4A (m/z = 1895.43). |
format | Online Article Text |
id | pubmed-6409522 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-64095222019-03-22 MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease Banach, Paulina Dereziński, Paweł Matuszewska, Eliza Matysiak, Jan Bochyński, Hubert Kokot, Zenon J. Nowak-Markwitz, Ewa Metabolites Article Gestational trophoblastic disease (GTD) is a group of highly aggressive, rare tumors. Human chorionic gonadotropin is a common biomarker used in the diagnosis and monitoring of GTD. To improve our knowledge of the pathology of GTD, we performed protein-peptide profiling on the urine of patients affected with gestational trophoblastic neoplasm (GTN). We analyzed urine samples from patients diagnosed with GTN (n = 26) and from healthy pregnant and non-pregnant controls (n = 17) using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). Ions were examined in a linear mode over a m/z range of 1000–10,000. All GTN urine samples were analyzed before and after treatment and compared with those of the controls. The statistical analyses included multivariate classification algorithms as well as ROC curves. Urine sample analyses revealed there were significant differences in the composition of the ions between the evaluated groups. Comparing the pre-treatment and group with the pregnant controls, we identified two discriminatory proteins: hemoglobin subunit α (m/z = 1951.81) and complement C4A (m/z = 1895.43). Then, comparing urine samples from the post-treatment cases with those from the non-pregnant controls, we identified the peptides uromodulin fragments (m/z = 1682.34 and 1913.54) and complement C4A (m/z = 1895.43). MDPI 2019-02-09 /pmc/articles/PMC6409522/ /pubmed/30744112 http://dx.doi.org/10.3390/metabo9020030 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Banach, Paulina Dereziński, Paweł Matuszewska, Eliza Matysiak, Jan Bochyński, Hubert Kokot, Zenon J. Nowak-Markwitz, Ewa MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title | MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title_full | MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title_fullStr | MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title_full_unstemmed | MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title_short | MALDI-TOF-MS Analysis in the Identification of Urine Proteomic Patterns of Gestational Trophoblastic Disease |
title_sort | maldi-tof-ms analysis in the identification of urine proteomic patterns of gestational trophoblastic disease |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6409522/ https://www.ncbi.nlm.nih.gov/pubmed/30744112 http://dx.doi.org/10.3390/metabo9020030 |
work_keys_str_mv | AT banachpaulina malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT derezinskipaweł malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT matuszewskaeliza malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT matysiakjan malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT bochynskihubert malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT kokotzenonj malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease AT nowakmarkwitzewa malditofmsanalysisintheidentificationofurineproteomicpatternsofgestationaltrophoblasticdisease |